Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 95 of 5804
-
Weekly injection helps shed pounds in major weight loss trial
Disease control CompletedThis study will look at the change in body weight from the start to the end of the study. The purpose of the study is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the medicine particip…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Lung cancer hope: drug combo aims to boost survival in Early-Stage disease
Disease control OngoingResearchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Bladder cancer patients may skip surgery with new drug combo
Disease control OngoingThe purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy.
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug may offer better protection against breast cancer return
Disease control OngoingPatients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence. More effective treatment options are needed for this patient population. This study will examine the efficac…
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Gene therapy shows promise for rare blindness disease
Disease control OngoingA clinical trial of AAV5-hRKp.RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Gene therapy offers hope for rare blindness
Disease control CompletedA clinical trial of AAV5-RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Immune cell therapy shows promise for aggressive blood cancer
Disease control Recruiting nowA Study of CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for hard-to-treat lung cancer: targeted drug plus immunotherapy tested
Disease control Recruiting nowThe Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 port…
Phase: PHASE2, PHASE3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Four-Drug cocktail aims to shrink pancreatic tumors before surgery
Disease control CompletedTo evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.
Phase: PHASE2 • Sponsor: HonorHealth Research Institute • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
HPV vaccine shows promise for japanese men in landmark trial
⭐️ VACCINE ⭐️ CompletedThe purposes of this phase 3, double-blind, placebo-controlled clinical study are to evaluate the efficacy of V503 in preventing human papillomavirus (HPV)-related anogenital persistent infection, and to evaluate the safety/tolerability of V503, in Japanese males who are 16 to 26…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:07 UTC
-
Bionic eye implant aims to bring back sight in advanced macular degeneration
Disease control OngoingThe objective of this study is to evaluate the efficacy and safety of the PRIMA System in patients with atrophic AMD. Eligible subjects will be implanted with the PRIMA Implant. The subjects will be assessed with various visual function and functional vision tests at defined time…
Phase: NA • Sponsor: Science Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Gene therapy shot could end need for repeated eye needles in diabetes
Disease control OngoingABBV-RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of Diabetic Retinopathy (DR) with and without Center-Involved Diabetic Macular Edema (CI-DME). DR is a chronic and progressive complication of diabetes mellitus. It is a sight-…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 26, 2026 17:53 UTC
-
Could a vaccine shield newborns from a deadly bacterial infection?
⭐️ VACCINE ⭐️ CompletedA randomised, placebo-controlled, double-blind study to evaluate the safety, tolerability and immunogenicity of the GBS-NN/NN2 (Recombinant protein vaccine against Group B Streptococcus) vaccine in women living with HIV and women without HIV, and their newborn babies from vaccina…
Phase: PHASE2 • Sponsor: Minervax ApS • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 16, 2026 00:00 UTC
-
Mouth cells could bring sight back to the blind
Disease control Recruiting nowSome severe ocular burns or other rare ocular pathologies can be associated with a total loss of corneal epithelial stem cells (i.e. Limbal Stem Cell Deficiency - LSCD), which leads to cornea invasion by the conjunctiva and a subsequent opacification. When LSCD is total and bilat…
Phase: PHASE1, PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Cord blood boost: new technique shows promise for tough leukemia cases
Disease control CompletedCord blood (CB) transplants are an option for patients lacking an HLA identical donor but are hampered by low cell dose, prolonged aplasia and high transplant related mortality. UM171, a novel and potent agonist of hematopoietic stem cell self renewal could solve this major limit…
Phase: PHASE2 • Sponsor: ExCellThera inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Gene therapy hope for boys with duchenne muscular dystrophy
Disease control OngoingThe study will evaluate the safety and efficacy of gene therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study with two thirds of participants assigned to gene therapy. The one third of participants who are randomized to the placebo arm will have an …
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Gene editing breakthrough? CRISPR therapy targets rare amyloidosis
Disease control CompletedThis study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NTLA-2001 in participants with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) and participants with hereditary transthyretin amyloidosis wit…
Phase: PHASE1 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Precision radiation boosts fight against deadly brain tumors
Disease control OngoingThis study will investigate whether or not intensified radiation therapy adapted during the radiation treatment course to high-risk, treatment-resistant tumor regions will improve overall survival in patients with newly diagnosed glioblastoma (GBM) compared to conventional chemor…
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can bariatric surgery save hearts? major trial aims to find out
Disease control Recruiting nowThe primary objective of this study is to evaluate if, in patients with severe obesity (body mass index (BMI) ≥30 kg/m2) and high-risk cardiovascular disease (CVD), bariatric surgery compared to medical weight management (MWM) safely reduces the risk of major cardiovascular event…
Phase: NA • Sponsor: Population Health Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Immunotherapy duo shows promise in Tough-to-Treat esophageal cancer
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of atezolizumab plus tiragolumab in combination with paclitaxel and cisplatin (PC) compared with atezolizumab matching placebo plus tiragolumab matching placebo plus PC as first-line treatment in participants with u…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC